ArticleCancer causes & control : CCC2026
Survival among US adults with post-cancer-diagnosis cigarette smoking cessation.
Article in Cancer causes & control : CCC, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundCurrent evidence on the impact of post-cancer-diagnosis cigarette smoking cessation on survival is largely based on small-scale studies with limited cancer types.
methodsThis retrospective cohort study included 8,120 adult cancer survivors from the 2000-2018 National Health Interview Survey Public-use Linked Mortality Files with death information through December 31, 2019. We performed propensity score weighting (PSW) and survival analysis to assess the association of smoking cessation within 3 years after a cancer diagnosis with all-cause mortality among adult cancer survivors of all cancer types, cancers with high relative survival rates, and four major cancers (lung, breast, prostate, and colorectal).
resultsApproximately 19.6% of cancer survivors who were cigarette smokers quit smoking within 3 years after their cancer diagnosis. Compared to those who did not quit, cancer survivors who quit had an additional median survival time (MST) of 4 (95% CI 3.1-4.9) years and a relatively lower risk of death (marginal hazard ratio (MHR) 0.86; 95% CI 0.76-0.98). A more pronounced survival benefit was found for survivors of cancers with a high 5-year relative survival rate (> 74%), where the quit group had a longer MST of 7 (95% CI 6.7-7.3) years and an MHR of 0.79 (95% CI 0.66-0.94). Except for colorectal cancer, significant survival benefits were also found for survivors of lung, prostate, and breast cancers.
conclusionBy integrating PSW with linked nationally representative data spanning nearly two decades, we demonstrated that smoking cessation within 3 years after a cancer diagnosis was associated with a significant survival advantage.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.